Phase II study: Gemcitabine (ribonucleotide reductase inhibitor) and Carboplatin (platinum inhibitor) in urothelial carcinoma

This Phase II trial at Fox Chase Cancer Center evaluates the efficacy and safety of gemcitabine plus carboplatin in patients with advanced urothelial carcinoma who have progressed following enfortumab vedotin and pembrolizumab. Participants receive regular infusions with scheduled labs, scans, and quality-of-life assessments while blood samples are collected for biomarker analyses to inform future treatment strategies.